Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme

Grossi, Francesco, Crinò, Lucio, Logroscino, Antonio, Canova, Stefania, Delmonte, Angelo, Melotti, Barbara, Proto, Claudia, Gelibter, Alain +13 more·2018·European Journal of Cancer
DOI 10.1016/j.ejca.2018.05.015

Cited by (110)

Items 101–110 of 110

  1. Lung Immunotherapy in the Elderly with NSCLC – the Who, the What, and the When
    Teodora Alexa‐Stratulat, Mihai Vasile Marinca, Ioana-Dana Alexa, Sabina A Antoniu · 2023 · Interdisciplinary cancer research
  2. Data from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
    Roberto Ferrara, Marie Naigeon, Édouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita et al. · 2023
  3. Adaptation du plan thérapeutique en fonction de l’âge
    R. Corre · 2024 · Revue des Maladies Respiratoires Actualités
  4. Prise en charge systémique du cancer bronchique non à petites cellules chez les sujets âgés
    Lucile Pabst, R. Corre, Élisabeth Quoix, Céline Mascaux · 2025 · Revue des Maladies Respiratoires Actualités
  5. Additional file 1 of Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
    Kurokawa, Kana, Yoichiro Mitsuishi, Shimada, Naoko, Kawakami, Yuta, Miura, Keita, Taichi Miyawaki, Asao, Tetsuhiko, Ko, Ryo, Takehito Shukuya, Rina Shibayama et al. · 2022 · Figshare
  6. Additional file 1 of Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study
    Song Guan, Ren, Kai, Zhang, Xuyu, Yan, Meng, Xue Li, Zhao, Lujun · 2023 · Figshare
  7. Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients
    Yufang Lu, Pengcheng Liu, Changxiu Ma, Hui Liu, Y. Zhang, Dahai Zhao · 2026 · BMC Cancer
  8. Chinese Expert Consensus on Immune Checkpoint Inhibitor Therapy for Elderly Patients with Advanced Non‐small Cell Lung Cancer (2025 Edition)
    Li Lin, Nie Xin, Wei Qian, Li Xu, Tian Yumeng, Wu Lin, Wang Jingyi, Wang Zhijie, Wang Mingzhao, Baoshan Cao et al. · 2026 · Aging Medicine
  9. Populations lymphocytaires circulantes exprimant PD-1 au cours des cancers bronchiques avancés, valeur prédictive de réponse aux inhibiteurs de PD-1/PD-L1
    Boris Duchemann · 2021 · theses.fr (ABES)
  10. Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?
    Abed Agbarya, Noa Shani Shrem, Asmah Miari, Ronen Brenner, Yulia Dudnik, Natalie Maimon Rabinovich, Amichay Meirovitz, Alexander Yakobson, Ahron Yehonatan Cohen, Nashat Abu Yasin et al. · 2026 · Frontiers in Immunology